AUG Therapeutics is a clinical-stage biotechnology company specializing in the acquisition and development of pharmaceuticals for rare pediatric and orphan diseases.
ABOUT US
AUG Therapeutics is a clinical stage biotechnology company specialized in the development of pharmaceuticals for rare pediatric and orphan diseases. AUG is on a conscionable mission to put patients suffering from rare and neglected disease and their families as our first priority. Our relentless efforts are dedicated to advancing patient care and addressing the unique challenges presented by these conditions.
PRODUCT PIPELINE
AUG-800s
AUG-803 and other AUG formulations in our pipeline represent monosaccharide substrate replacement therapies with established therapeutic utility for the treatment of Congenital Disorders of Glycosylation. Oral administration of these substrates replenishes critical metabolic intermediates that are reduced or absent due to genetic mutation, overcoming single enzyme defects to support glycoprotein synthesis, maintenance and function.
CDG represent a large group of rare inherited diseases affecting glycosylation, the process of adding sugar-building blocks (also called glycans) to proteins or fats (lipids). When these sugar molecules are added to proteins they form glycoproteins, and when they are added to fats they form glycolipids. This process involves many different genes encoding many different proteins, such as enzymes. Not having enough of one of these enzymes can lead to many symptoms and may affect multiple organs. CDG can affect any part of the body, can have a wide variety of symptoms, and can range from mild to severe, disabling, or life-threatening. CDG are usually present from infancy. Individual CDG are caused by changes (mutations) in a specific gene.
AUG-803 (L-fucose):
AUG-803 is a therapeutic dose of L-fucose currently in development for the treatment of leukocyte adhesion deficiency type II (LAD II), also known as SLC35C1-CDG.
Targeting Glycosylation Defects in LAD II:
-
LAD II is caused by loss of function mutations in the SLC35C1 gene encoding a GDP-fucose transporter found in the Golgi apparatus, where it acts as the donor substrate for protein fucosylation. Currently, there is no approved product for the treatment of LAD II.
-
AUG-803 is an oral formulation of L-fucose that replenishes critical metabolic intermediates, reduced or absent due to a genetic variant, to support glycoprotein synthesis, maintenance, and function.
CLINICAL STUDIES
AUG Therapeutics’ clinical trials are listed on www.ClinicalTrials.gov. Visit the site and search the term “AUG-803”, “AUG-801”, or “AUG-802”. If you locate a clinical study with a participating site that you are interested in, you or your physician may contact that site directly for more information. Our goal is to ensure that eligible patients can access our investigational drugs at the appropriate time and in the appropriate manner. If you have questions, please complete the adjacent form.
Partnerships
AUG Therapeutics is always looking to expand its portfolio of late-stage product development candidates in rare diseases with unmet needs; for more information on our partnerships or if you would like to become a partner, please contact us at info@augtx.com
Joining AUG Therapeutics offers you a chance to be part of a dynamic and growing company that values its people and prioritizes a positive culture. We foster an environment that provides numerous avenues for personal and professional growth within a thriving organization. If you are interested in exploring your career opportunities at AUG Therapeutics, we encourage you to reach out to us directly at info@augtx.com for more information.
Equal Opportunity Employer:
At AUG, we uphold a firm policy against any form of discrimination towards our employees or applicants based on race, color, religion, sex, sexual orientation, gender identity, national origin, age, marital status, genetic information, disability, or protected veteran status. We are dedicated to taking affirmative action to ensure equal employment opportunities and advancement for all individuals, regardless of the aforementioned characteristics, and making employment decisions solely based on valid job requirements. This policy applies to all aspects of employment, including but not limited to recruitment, hiring, promotion, transfer, demotion, termination, rates of pay, compensation, and selection for training, including apprenticeship, at all employment levels. We are committed to fostering a workplace where employees and applicants are not subjected to harassment on the basis of any protected characteristic. Furthermore, we strictly prohibit any form of retaliation, including intimidation, threats, or coercion, against employees or applicants who voice objections to discrimination, engage in the process of filing a complaint, provide assistance in a review, investigation, or hearing, or seek to exercise their legal rights under applicable laws. Our aim is to create an inclusive and respectful work environment where everyone can thrive and contribute to our collective success.